Zcash Privacy Demand Rises as AI Exposes Bitcoin Transactions 
Australia Consumer Confidence Plunges as RBA Rate Hike Hits Households 
Yes, government influences wages – but not just in the way you might think 
OKX Raises Fresh Funding at $25 Billion Valuation 
World Bank Raises South Asia Growth Forecast to 6.9% 
LG Electronics Shares Slide as Q3 Profit Misses Estimates 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Office design isn’t keeping up with post-COVID work styles - here’s what workers really want 
Anthropic Expands Claude Access for Cyber Defense Teams 
6 simple questions to tell if a ‘finfluencer’ is more flash than cash 
European Stocks Diverge as French Fiscal Crisis Hits CAC 40 
3 clinical-grade skincare creams you really shouldn’t buy online 
Heritage, desire and diplomacy: why China still values scotch whisky 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Samsung, SK Hynix Shares Fall Ahead of Q3 Earnings 
Debate over H-1B visas shines spotlight on US tech worker shortages 
Japan Real Wages Rise 1.5%, Supporting BOJ Rate Hikes 
Add as a preferred source on Google
Coca-Cola Japan and Kirin Holdings will develop health drinks that contain the live bacteria, lactococcus lactis strain plasma (LC-Plasma), an ingredient patented by Kirin that is used in the company's health drinks.
Kirin claims that the live bacteria boosts immunity in healthy people.
Kirin is the first among companies that make foods and beverages they claim to boost immunity to have been approved by Japan's Consumer Affairs Agency in 2020 to advertise its products as such.
Coca-Cola Japan plans to put LC-Plasma into three of its brands, Georgia, Irohasu, and Minute Maid.
The Consumer Affairs Agency has also given the go-ahead for the drinks to be advertised as having the advantage.
The partnership demonstrates Coca-Cola Japan's intention to improve its position in the health beverage market. According to market research firm Inryo Soken, Coca-Cola has a 26 percent market share in soft drinks but has not advanced significantly in the market for health beverages.
On the other hand, Kirin is increasing sales of its LC-Plasma component and sees health products as its next area of growth. It anticipates that by 2027, sales of health drinks will have increased fivefold from their current level to 50 billion yen.
Taisho Pharmaceutical Holdings, as well as candy manufacturers including Morinaga & Co. and Kanro, have already purchased the component from Kirin.
Although supplying a rival with distinctive ingredients would negate Kirin's advantage, collaborating with Coca-Cola might let it expand its market.
